| Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study A Rauch, Z Kutalik, P Descombes, T Cai, J Di Iulio, T Mueller, M Bochud, ... Gastroenterology 138 (4), 1338-1345. e7, 2010 | 1474 | 2010 |
| Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study G Greub, B Ledergerber, M Battegay, P Grob, L Perrin, H Furrer, ... The Lancet 356 (9244), 1800-1805, 2000 | 1252 | 2000 |
| Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study B Ledergerber, M Egger, M Opravil, A Telenti, B Hirschel, M Battegay, ... The Lancet 353 (9156), 863-868, 1999 | 1116 | 1999 |
| Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of … AJ Rodger, V Cambiano, T Bruun, P Vernazza, S Collins, O Degen, ... The Lancet 393 (10189), 2428-2438, 2019 | 1058 | 2019 |
| Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study M Egger, B Hirschel, P Francioli, P Sudre, M Wirz, M Flepp, M Rickenbach, ... Bmj 315 (7117), 1194-1199, 1997 | 773 | 1997 |
| Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study B Hasse, B Ledergerber, H Furrer, M Battegay, B Hirschel, M Cavassini, ... Clinical infectious diseases 53 (11), 1130-1139, 2011 | 753 | 2011 |
| AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study B Ledergerber, M Egger, V Erard, R Weber, B Hirschel, H Furrer, ... Jama 282 (23), 2220-2226, 1999 | 633 | 1999 |
| COVID-19 epidemic in Switzerland: on the importance of testing, contact tracing and isolation S Marcel, AL Christian, N Richard, S Silvia, H Emma, F Jacques, Z Marcel, ... Swiss medical weekly 150, w202205, 2020 | 604 | 2020 |
| Major clinical outcomes in antiretroviral therapy (ART)–naive participants and in those not receiving ART at baseline in the SMART study Strategies for Management of Antiretroviral Therapy (SMART) Study Group The Journal of infectious diseases 197 (8), 1133-1144, 2008 | 579 | 2008 |
| CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study GR Kaufmann, L Perrin, G Pantaleo, M Opravil, H Furrer, A Telenti, ... Archives of internal medicine 163 (18), 2187-2195, 2003 | 562 | 2003 |
| Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24-or 96-well plates M Battegay, S Cooper, A Althage, J Bänziger, H Hengartner, ... Journal of virological methods 33 (1-2), 191-198, 1991 | 528 | 1991 |
| Decreasing mortality and changing patterns of causes of death in the S wiss HIV C ohort S tudy R Weber, M Ruppik, M Rickenbach, A Spörri, H Furrer, M Battegay, ... HIV medicine 14 (4), 195-207, 2013 | 494 | 2013 |
| Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study J Fellay, B Ledergerber, E Bernasconi, H Furrer, M Battegay, B Hirschel, ... The Lancet 358 (9290), 1322-1327, 2001 | 490 | 2001 |
| Immune reconstitution in HIV-infected patients KH Mayer, HH Hirsch, G Kaufmann, P Sendi, M Battegay Clinical Infectious Diseases 38 (8), 1159-1166, 2004 | 457 | 2004 |
| Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study N Friis-Møller, R Thiebaut, P Reiss, R Weber, A D'Arminio Monforte, ... European journal of cardiovascular prevention & rehabilitation 17 (5), 491-501, 2010 | 451 | 2010 |
| characteristics, determinants, and clinical relevance of CD4 T cell recovery to< 500 cells/µL in HIV type 1—infected individuals receiving potent antiretroviral therapy GR Kaufmann, H Furrer, B Ledergerber, L Perrin, M Opravil, P Vernazza, ... Clinical infectious diseases 41 (3), 361-372, 2005 | 437 | 2005 |
| Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials HC Bucher, LE Griffith, GH Guyatt, P Sudre, M Naef, P Sendi, M Battegay Aids 13 (4), 501-507, 1999 | 430 | 1999 |
| Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice M Battegay, D Moskophidis, A Rahemtulla, H Hengartner, TW Mak, ... Journal of virology 68 (7), 4700-4704, 1994 | 408 | 1994 |
| Discontinuation of Primary Prophylaxis against Pneumocystis carinii Pneumonia in HIV-1–Infected Adults Treated with Combination Antiretroviral Therapy H Furrer, M Egger, M Opravil, E Bernasconi, B Hirschel, M Battegay, ... New England Journal of Medicine 340 (17), 1301-1306, 1999 | 357 | 1999 |
| Fibroblasts as efficient antigen-presenting cells in lymphoid organs TM Kündig, MF Bachmann, C DiPaolo, JJL Simard, M Battegay, H Lother, ... Science 268 (5215), 1343-1347, 1995 | 355 | 1995 |
